Zydus Lifesciences Limited (ZYDUSLIFE:NSE)の戦略的SWOTと財務分析

Report Overview

Report Summary

Zydus Lifesciences Limited Strategic SWOT Analysis and Financial Insights – A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends Report is a comprehensive and easily accessible overview of Zydus Lifesciences Limited’s business operations. It provides a detailed analysis of the company’s financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company’s performance.

The report begins with in-depth information about Zydus Lifesciences Limited including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company’s key attributes.

Next, the report assesses Zydus Lifesciences Limited’s strategic standing through various analyses. The ESG spotlight evaluates the company’s environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company’s internal strengths and weaknesses, as well as external opportunities and threats. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Zydus Lifesciences Limited’s overall strategic standing and supports informed decision-making and strategic planning.

The report also covers Zydus Lifesciences Limited’s financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Zydus Lifesciences Limited’s financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors’ operations.

Finally, the report includes recent news and deal activities undertaken by Zydus Lifesciences Limited enhancing awareness of the company’s business trends, growth perspectives, and more.

Key Highlights

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is a leading Indian pharmaceutical company with a rich legacy dating back to 1952, founded by Mr. Ramanbhai B. Patel. Headquartered in Ahmedabad, India, the company has grown into a fully integrated global healthcare provider, delivering comprehensive solutions across the pharmaceutical value chain. Its operations include formulations, active pharmaceutical ingredients, vaccines, biosimilars, complex products, animal health, and wellness products, supported by over 30 manufacturing plants across India, the USA, and Brazil. The company employs 27,917 people and conducts research through 1,500 scientists across 19 sites, focusing on new chemical entities, biologics, and vaccines to address unmet healthcare needs. Zydus has a strong presence in regulated markets such as the US and Europe, including France and Spain, as well as in Latin America, South Africa, and 25 emerging markets worldwide. Renowned for innovation and excellence, Zydus has received multiple national and international awards, including recognition for corporate social responsibility and pharmaceutical innovation. The company continues to drive healthcare solutions globally, staying committed to creating healthier and happier communities.

Zydus Lifesciences Limited in the News:-

2025-07-29 – Zydus announces completion of the acquisition of an 85.6% stake in Amplitude Surgical and upcoming filing of a simplified tender offer
2025-07-24 – Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg
2025-07-15 – Zydus receives final approval from USFDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg
2025-06-18 – Closure of USFDA inspection at Zydus’ oncology injectable plant at Ahmedabad
2025-06-03 – Zydus gets exclusive licensing rights for next gen immuno-oncology platforms from the US based Agenus

Scope

• Tactical Analysis:- Various strategic frameworks to gain insights into a Zydus Lifesciences Limited’s competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
• Business Strategy:- Contributes to shaping the Zydus Lifesciences Limited’s overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
• Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company’s future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
• Company Fundamentals:- These fundamentals offer valuable insights into the company’s history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
• Competitive Landscape:- An identification of the Zydus Lifesciences Limited’s main competitors, providing insights into the competitive landscape it operates in.

Reasons to Buy

• Comprehensive Understanding of the Zydus Lifesciences Limited’s internal and external factors through SWOT analysis, Financial Analysis, and Competitors Benchmarking.
• Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
• Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
• Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
• Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
• Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company Zydus Lifesciences Limited:

• Zydus Lifesciences Limited PESTLE Analysis
• Zydus Lifesciences Limited Value Chain Analysis
• Zydus Lifesciences Limited Porter’s Five Forces Analysis
• Zydus Lifesciences Limited VRIO Analysis
• Zydus Lifesciences Limited BCG Analysis
• Zydus Lifesciences Limited Segmentation, Targeting and Positioning (STP) Analysis
• Zydus Lifesciences Limited Ansoff Matrix Analysis

Table of Contents

Table of Contents 2
Tables 6
Charts 7
Zydus Lifesciences Limited – Key Company Facts 8
Zydus Lifesciences Limited – Company Description 9
Zydus Lifesciences Limited – Top Executives 10
Zydus Lifesciences Limited – Head Office & Locations 11
Head Office – Country 11
Zydus Lifesciences Limited – Products and Services 12
Products 12
Services 13
Zydus Lifesciences Limited – Corporate Strategy 14
Zydus Lifesciences Limited – Business Description 18
Pharmaceuticals Segment 18
Consumer Products Segment 19
Zydus Lifesciences Limited – ESG Spotlight 20
Environment 20
Social 21
Corporate Governance 21
Zydus Lifesciences Limited – SWOT Analysis 23
Overview 23
Strengths 25
Weaknesses 28
Opportunities 30
Threats 32
Zydus Lifesciences Limited – Financial Deep Dive 34
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 34
Profit and Loss Statement 36
Summary of Profit and Loss Statement 36
Balance Sheet 40
Summary of Balance Sheet 40
Cash Flow Statement 44
Summary of Cash Flow Statement 44
Key Financial Ratio Analysis 48
Zydus Lifesciences Limited – Ratio Charts 50
Activity Ratio Charts 50
Growth Ratios Charts 51
Leverage Ratio Charts 55
Liquidity Ratio Charts 57
Profitability Ratio Charts 59
Competing Players 61
Snapshot of Competing Players 62
Aurobindo Pharma Ltd 62
Key Company Facts 62
Company Description 62
Key Financials 63
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 63
Key Financial Ratio Analysis 68
Cipla Limited 70
Key Company Facts 70
Company Description 70
Key Financials 71
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 71
Key Financial Ratio Analysis 76
Dr. Reddy’s Laboratories Ltd 78
Key Company Facts 78
Company Description 78
Key Financials 79
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 79
Key Financial Ratio Analysis 84
Lupin Limited 86
Key Company Facts 86
Company Description 86
Key Financials 87
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 87
Key Financial Ratio Analysis 92
Sun Pharmaceutical Industries Limited 94
Key Company Facts 94
Company Description 94
Key Financials 95
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 95
Key Financial Ratio Analysis 100
Zydus Lifesciences Limited – In the News 102
29-Jul-2025 – Zydus announces completion of the acquisition of an 85.6% stake in Amplitude Surgical and upcoming filing of a simplified tender offer 102
24-Jul-2025 – Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg 102
15-Jul-2025 – Zydus receives final approval from USFDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg 103
18-Jun-2025 – Closure of USFDA inspection at Zydus’ oncology injectable plant at Ahmedabad 103
Zydus Lifesciences Limited – Key Deals 104
03-Jun-2025 – Zynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reach 104
03-Jun-2025 – Zydus to enter global biologics CDMO business Plans to acquire Agenus’ U.S. manufacturing facilities to accelerate development of innovative therapies 105
25-Apr-2025 – Zydus Lifesciences Limited signs purchase agreement with PAI Partners and other shareholders to acquire a majority stake in Amplitude Surgical SA 105
11-Mar-2025 – Zydus enters exclusive negotiations with PAI Partners and other shareholders to acquire a majority stake in Amplitude Surgical, France 106
14-Feb-2025 – Zydus and Beihai Biotech sign an exclusive licensing, supply and commercialization agreement for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product for the US market 107
23-Aug-2024 – Zydus to acquire 50% stake in Sterling Biotech from Perfect Day to enter into fermentation-based protein business 107
18-Jan-2024 – Zydus and Synthon enter into an exclusive licensing and supply agreement for Palbociclib Tablets (generic version of IBRANCE) for the US market 108
Appendix 109
Definitions 109
SWOT Analysis 109
PESTLE Analysis 109
Value Chain Analysis 109
ESG Spotlight 109
Financial Deep Dive 109
Financial Ratios 110
Activity Ratios 110
Growth Ratios 112
Leverage Ratios 115
Liquidity Ratios 117
Market Ratios 119
Profitability Ratios 121
Research Methodology 123
Disclaimer 124
Contact Us 124

List of Tables

Table 1: Zydus Lifesciences Limited – Company Facts 8
Table 2: Zydus Lifesciences Limited – Digital Presence 8
Table 3: Zydus Lifesciences Limited – Top Executives 10
Table 4: Zydus Lifesciences Limited – Products 12
Table 5: Zydus Lifesciences Limited – Services 13
Table 6: Zydus Lifesciences Limited – Share Price Trend – Jun-2025 to Jun-2026 34
Table 7: Zydus Lifesciences Limited – Profit and Loss Statement – 2023-2026 37
Table 8: Zydus Lifesciences Limited – Balance Sheet – 2023-2026 41
Table 9: Zydus Lifesciences Limited – Cash Flow Statement – 2023-2026 45
Table 10: Zydus Lifesciences Limited – Ratio Analysis – 2023-2026 48
Table 11: Zydus Lifesciences Limited – Competing Players 61
Table 12: Competing Players – Aurobindo Pharma Ltd – Key Company Facts 62
Table 13: Aurobindo Pharma Ltd – Share Price Trend – Jun-2025 to Jun-2026 63
Table 14: Competing Players – Aurobindo Pharma Ltd – Profit and Loss Statement – 2023-2026 65
Table 15: Aurobindo Pharma Ltd – Balance Sheet 2023-2026 66
Table 16: Aurobindo Pharma Ltd – Cash Flow Statement 2023-2026 67
Table 17: Aurobindo Pharma Ltd – Ratio Analysis – 2023-2026 68
Table 18: Competing Players – Cipla Limited – Key Company Facts 70
Table 19: Cipla Limited – Share Price Trend – Jun-2025 to Jun-2026 71
Table 20: Competing Players – Cipla Limited – Profit and Loss Statement – 2023-2026 73
Table 21: Cipla Limited – Balance Sheet 2023-2026 74
Table 22: Cipla Limited – Cash Flow Statement 2023-2026 75
Table 23: Cipla Limited – Ratio Analysis – 2023-2026 76
Table 24: Competing Players – Dr. Reddy’s Laboratories Ltd – Key Company Facts 78
Table 25: Dr. Reddy’s Laboratories Ltd – Share Price Trend – Jun-2025 to Jun-2026 79
Table 26: Competing Players – Dr. Reddy’s Laboratories Ltd – Profit and Loss Statement – 2023-2026 81
Table 27: Dr. Reddy’s Laboratories Ltd – Balance Sheet 2023-2026 82
Table 28: Dr. Reddy’s Laboratories Ltd – Cash Flow Statement 2023-2026 83
Table 29: Dr. Reddy’s Laboratories Ltd – Ratio Analysis – 2023-2026 84
Table 30: Competing Players – Lupin Limited – Key Company Facts 86
Table 31: Lupin Limited – Share Price Trend – Jun-2025 to Jun-2026 87
Table 32: Competing Players – Lupin Limited – Profit and Loss Statement – 2023-2026 89
Table 33: Lupin Limited – Balance Sheet 2023-2026 90
Table 34: Lupin Limited – Cash Flow Statement 2023-2026 91
Table 35: Lupin Limited – Ratio Analysis – 2023-2026 92
Table 36: Competing Players – Sun Pharmaceutical Industries Limited – Key Company Facts 94
Table 37: Sun Pharmaceutical Industries Limited – Share Price Trend – Jun-2025 to Jun-2026 95
Table 38: Competing Players – Sun Pharmaceutical Industries Limited – Profit and Loss Statement – 2023-2026 97
Table 39: Sun Pharmaceutical Industries Limited – Balance Sheet 2023-2026 98
Table 40: Sun Pharmaceutical Industries Limited – Cash Flow Statement 2023-2026 99
Table 41: Sun Pharmaceutical Industries Limited – Ratio Analysis – 2023-2026 100

List of Figures

Figure 1: Zydus Lifesciences Limited – SWOT Analysis 24
Figure 2: Zydus Lifesciences Limited – Average Share Price Trend – Jun-2025 to Jun-2026 35
Figure 3: Zydus Lifesciences Limited – Profit and Loss Statement – 2023-2026 39
Figure 4: Zydus Lifesciences Limited – Balance Sheet – 2023-2026 43
Figure 5: Zydus Lifesciences Limited – Cash Flow Statement 2023-2026 47
Figure 6: Zydus Lifesciences Limited – Activity Ratio Charts 50
Figure 7: Zydus Lifesciences Limited – Growth Ratio Charts (Value %) 51
Figure 8: Zydus Lifesciences Limited – Leverage Ratio Charts 55
Figure 9: Zydus Lifesciences Limited – Liquidity Ratio Charts 57
Figure 10: Zydus Lifesciences Limited – Profitability Ratio Charts (Value %) 59
Figure 11: Aurobindo Pharma Ltd – Average Share Price Trend – Jun-2025 to Jun-2026 64
Figure 12: Aurobindo Pharma Ltd – Profit and Loss Statement – 2023-2026 65
Figure 13: Aurobindo Pharma Ltd – Balance Sheet – 2023-2026 66
Figure 14: Aurobindo Pharma Ltd – Cash Flow Statement 2023-2026 67
Figure 15: Cipla Limited – Average Share Price Trend – Jun-2025 to Jun-2026 72
Figure 16: Cipla Limited – Profit and Loss Statement – 2023-2026 73
Figure 17: Cipla Limited – Balance Sheet – 2023-2026 74
Figure 18: Cipla Limited – Cash Flow Statement 2023-2026 75
Figure 19: Dr. Reddy’s Laboratories Ltd – Average Share Price Trend – Jun-2025 to Jun-2026 80
Figure 20: Dr. Reddy’s Laboratories Ltd – Profit and Loss Statement – 2023-2026 81
Figure 21: Dr. Reddy’s Laboratories Ltd – Balance Sheet – 2023-2026 82
Figure 22: Dr. Reddy’s Laboratories Ltd – Cash Flow Statement 2023-2026 83
Figure 23: Lupin Limited – Average Share Price Trend – Jun-2025 to Jun-2026 88
Figure 24: Lupin Limited – Profit and Loss Statement – 2023-2026 89
Figure 25: Lupin Limited – Balance Sheet – 2023-2026 90
Figure 26: Lupin Limited – Cash Flow Statement 2023-2026 91
Figure 27: Sun Pharmaceutical Industries Limited – Average Share Price Trend – Jun-2025 to Jun-2026 96
Figure 28: Sun Pharmaceutical Industries Limited – Profit and Loss Statement – 2023-2026 97
Figure 29: Sun Pharmaceutical Industries Limited – Balance Sheet – 2023-2026 98
Figure 30: Sun Pharmaceutical Industries Limited – Cash Flow Statement 2023-2026 99

---

---